XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - Contingent Consideration Classified as Equity
9 Months Ended 12 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Credit Derivatives [Line Items]    
Revenue volatility (as a percent) 25.00% 25.00%
Average probability of commercialization (as a percent) 12.50% 12.50%
Market price of risk 0.03 0.03
Credit rating BB BB
Equity risk premium (as a percent) 6.00% 6.00%